Skip to content

Dietary fiber improves skeletal muscle mass based on intestinal function regulation: a randomized controlled trial

Dietary fiber improves skeletal muscle mass based on intestinal function regulation: a randomized controlled trial

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000040709
Enrollment
Unknown
Registered
2020-12-08
Start date
2020-12-31
Completion date
Unknown
Last updated
2021-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ICU acquired weakness

Interventions

control:total integrate protein formula without dietary fiber
Experimental group:total integrate protein formula plus 24g DF

Sponsors

The General Hospital of Western Command Theater of PLA
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Patients in surgical ICU with craniocerebral trauma, cerebral hemorrhage, organ surgery, limb and spinal surgery were the first choice; (2) Aged between 18 and 65 years old; (3) the 24-hour NUTRIC score was greater than or equal to 5 points, APACHE II score was greater than 10 points; (4) voluntary participation in this study.

Exclusion criteria

Exclusion criteria: (1) There are various bone metabolism or muscle diseases, such as myasthenia gravis; (2) NUTRIC score less than 5; (3) expected ICU stay less than 7 days; (4) accompanied by tumor or type I diabetes, ckd 4-5 of basic diseases, with severe liver disease; (5) family members of patients refused to participate in the study; (6) patients who could not receive enteral nutrition supplements; (7) accompanied by intestinal diseases or factors affecting digestion, absorption, metabolism or excretion; (8) accompanied by thyroid dysfunction or endocrine and metabolic diseases; (9) pregnant or lactating women; (10) history of mental illness; (11) previous history of allergy to drugs known to be used; (12) previous diarrhea, constipation, or intestinal inflammation; (13) top two in the group Weeks of use of antibiotics, probiotics, prebiotics, synbiotics preparations.

Design outcomes

Primary

MeasureTime frame
average blood glucose level;IGF-1;myostatin;

Secondary

MeasureTime frame
Intestinal flora (Bifidobacterium / Enterobacter Kobe value);albumin;pre-albumin;Globulin;Retinol binding protein;Transferrin;blood creatinine;urea nitrogen;endogenocreatinine clearance rate;ALT;AST;CRP;IL-1;IL-6;TNF-alpha;

Countries

China

Contacts

Public ContactFu-xiang Li, Ning Lin

The General Hospital of Western Command Theater of PLA

525845176@qq.com+86 13980074996

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026